Podcasts about nvo

„Mēs varam aizvērt aizkarus un izvēlēties neredzēt, un mēs varam izvēlēties runāt." Šajā epizodē tiekos ar Ilutu Lāci, sievieti, kura jau 26 gadus, kopā ar savu komandu vada centru "MARTA". Mūsu saruna bija ieplānota jau sen, un šķiet, ka tieši tagad, pēc visa, kas noticis pēdējā pusgada laikā, tā ir vajadzīga vairāk nekā jebkad. Domāju kāpēc vispār NVO sauc par nevalstiskām organizācijām. Tā it kā tās nemaz nebūtu ar valsti saistītas, taču cik daudz atbalsta sniedz un iespēju dod cilvēkiem, kuri vēlas iesaistīties, sajūt sevī impulsu, misiju, vēlmi radīt pārmaiņas. Runājam par to: kā personīgā misija par brīvības sajūtu ir veidojusi vēlmi veidot biedrību un sniegt palīdzīgu roku sievietēm kāpēc vēl joprojām dzīvojam stereotipu un pieņēmumu maldos par vainīgo ko Ilutai nozīmē darbs centrā un iesaistīties ne tikai Latvijā, bet pasaulē ko Iluta ir sapratusi šo gadu laikā par vardarbību un sabiedrību un kā Iluta pati atgūst spēku dienā pēc dienas, kad ikdiena ir pilna smagu stāstu Pēc mūsu sarunas vēl ilgi paliku pārdomās par savu pieredzi, par dzirdēto, sajusto un aizdomājos, cik patiesībā sistēmai ir vajadzīgs ilgs laiks, lai ierastos režīmus mainītu, paternus izskaustu. Mani no sirds iedvesmoja Ilutas pieredze, stāstītais un, lai arī jūs iedvesmo šis misijas ceļš! Centrs MARTA ir vadošā sieviešu tiesību aizstāvības un atbalsta nevalstiskā organizācija Latvijā, kas sniedz sociālās, juridiskās un psiholoģiskās konsultācijas. Organizācija atrodas Rīgā un palīdz vardarbībā cietušajiem. HR PODCAST ir sarunas par tēmām, kas aktuālas personāla vadības ekspertiem, CEO, vadītājiem organizācijās, ikvienam, kam svarīga darba vide. Raidieraksts, kurā tiekamies ar cilvēkresursu vadības ekspertiem, profesionāļiem, praktiķiem. Uzklausām viedokļus un pieredzes, kā arī uzdodam jautājumus par jaunākajiem rīkiem, kādus lietot, lai vēl labāk sniegtu stratēģisku atbalstu biznesam. Sarunas vada Ilze Medne.Rubrika CEO dienasgrāmata: Sarunas ar vadītājiem un uzņēmumu CEO, par viņu ikdienas pieredzi esot vadītāja amatā. Par līderību, organizācijas attīstību un sadarbību ar HR.

Krustpunktā lielā intervija: Latvijas Veselības un sociālās aprūpes darbinieku arodbiedrības (LVSADA) vadītāja Līga Bāriņa. Esošā valdība ir darbu sākusi salīdzinoši īsu laiku pirms vēlēšanām, tādēļ katram ministram tika prasīts noteikt trīs prioritātes, ar ko strādāt. Veselības aprūpē tās saistītas ar slimnīcu tīkla reorganizāciju, pacientu vienotā pieraksta izveidi un zāļu reformu. Ko par šī prioritātēm un valdības pirmo pusotru darba mēnesi domā veselības aprūpē strādājošie? Tomēr vispirms īsi par diskusiju, kas tagad norit par nevalstisko sektoru, jo arī arodbiedrība arī ir viens no nevalstisko organizāciju (NVO) veidiem. Premjera izteikumi par "parunāšanās apmaksāšanu" valdības Memoranda padomes sēdē izraisīja plašu rezonansi. NVO pārstāvji piekrīt, ka finansējuma uzraudzībai, ko valsts iegulda nevalstiskajā sektorā, ir jābūt un tāda jau ir, bet vairāk satraucas par efektu, ko šādi izteikumi izraisa kopumā, jo bažījās, ka tie grauj uzticību nevalstiskajam sektoram kā tādam. Daudzas reakcijas publiski lasāmajās diskusijās arī ir  NVO noniecinošas.  

Krustpunktā lielā intervija: Latvijas Veselības un sociālās aprūpes darbinieku arodbiedrības (LVSADA) vadītāja Līga Bāriņa. Esošā valdība ir darbu sākusi salīdzinoši īsu laiku pirms vēlēšanām, tādēļ katram ministram tika prasīts noteikt trīs prioritātes, ar ko strādāt. Veselības aprūpē tās saistītas ar slimnīcu tīkla reorganizāciju, pacientu vienotā pieraksta izveidi un zāļu reformu. Ko par šī prioritātēm un valdības pirmo pusotru darba mēnesi domā veselības aprūpē strādājošie? Tomēr vispirms īsi par diskusiju, kas tagad norit par nevalstisko sektoru, jo arī arodbiedrība arī ir viens no nevalstisko organizāciju (NVO) veidiem. Premjera izteikumi par "parunāšanās apmaksāšanu" valdības Memoranda padomes sēdē izraisīja plašu rezonansi. NVO pārstāvji piekrīt, ka finansējuma uzraudzībai, ko valsts iegulda nevalstiskajā sektorā, ir jābūt un tāda jau ir, bet vairāk satraucas par efektu, ko šādi izteikumi izraisa kopumā, jo bažījās, ka tie grauj uzticību nevalstiskajam sektoram kā tādam. Daudzas reakcijas publiski lasāmajās diskusijās arī ir  NVO noniecinošas.  

In this midyear live stream, Jason and Jeff look back at a chaotic first half of 2026, dissecting how the broader market continues to push ahead despite global geopolitical tensions. The hosts dive into a data-backed re-evaluation of their personal portfolios, checking in on massive year-to-date winners like Datadog and Texas Instruments, while reflecting on painful laggards like The Trade Desk. They outline exactly how to value speculative, pre-revenue plays like QuantumScape following its fresh Honda partnership, crown a new winner in the monthly portfolio contest, and deliver a harsh warning on consumer-packaged goods like Celsius as they face private-label replication from big-box competitors. 01:21 Welcome and Community Chat 03:27 Today's Agenda Midyear Check 06:25 Market Vibes and Sector Moves 17:41 Top Portfolio Winners YTD 23:49 Adding to Winners Debate 30:21 Worst Performers  39:04 QuantumScape Buy Debate 47:03 Portfolio Contest Winner 52:58 Celsius Stock Breakdown Companies mentioned: ASML, CELH, COST, CRWD, DDOG, FTNT, HMC, ISRG, LLY, META, MRNA, NOW, NVO, PEP, QS, TTD, TXN Find where to listen & subscribe,  portfolio contests, and contact information at https://investingunscripted.com ***************************************** To get 15% off any paid plan at fiscal.ai, visit https://fiscal.ai/unscripted Listen to the Chit Chat Stocks Podcast for discussions on stocks, financial markets, super investors, and more. Follow the show on Spotify, Apple Podcasts, or YouTube ***************************************** Join our Patreon Subscribe to our portfolio on Savvy Trader. Use code Unscripted2026 for 30% off a one-year subscription! Learn more about your ad choices. Visit megaphone.fm/adchoices

Pēc sešu gadu pārtraukuma Latvijas folkloras pētnieki atkal devušies zinātniskajā ekspedīcijā. Šoreiz uz Nautrēnu kultūrtelpu Latgalē, kas pērn rudenī tika iekļauta Latvijas Nemateriālā kultūras mantojuma sarakstā. Šovakar, 10. jūlijā, ar pasākumu Nautrēnu kultūras namā noslēgsies šīs nedēļas ekspedīcija, kurā 20 pētnieki dokumentēja vietējo iedzīvotāju stāstus par dzīvi, kultūras mantojumu, valodu, kultūrtelpas sajūtu, drošību un citiem būtiskiem jautājumiem. Savāktie materiāli nu papildinās Latvijas Folkloras krātuvi un palīdzēs saglabāt un stiprināt gan Nautrēnu, gan citas Latvijas kultūrtelpas un to kopienas. Lai aprunātos ar ekspedīcijas vadītāju un Latvijas Folkloras krātuves pētnieku Sandi Laimi, Latviešu folkloras krātuves vadītāju Ritu Zaru un Latvijas Kultūras akadēmijas profesori Rūtu Muktupāvelu, uz Nautrēniem bija devusies Guna Zvīdre. Rēzeknes novada Nautrēnu pagastā šonedēļ zinātniskajā ekspedīcijā rosās Latvijas Folkloras krātuves, Latvijas Kultūras akadēmijas, RTU Rēzeknes akadēmijas, Rīgas Stradiņa universitātes un latgaliešu kultūras kustības “Volūda” pētnieki. Sadalījušies desmit divu cilvēku grupās, viņi apbraukā vietējos iedzīvotājus un audio, video un fotomateriālos dokumentē Nautrēnu kultūrtelpu. Kā uzsver pētnieki, kultūrtelpa nav vieta, bet cilvēki. Un jāatzīst, Nautrēnu pagasts tiešām ir bagāts ar spilgtām personībām. Piemēram, netālu no Rogovkas, Zaļmuižā, bijušajā muižas ēkā dzīvo un rosās metālmākslinieks Jānis Ļubka. Par to, ko mūsdienās vēl iespējams atrast folkloras ekspedīcijās, jautāju Latvijas Folkloras krātuves pētniekam Sandim Laimem. Sandis Laime: „Skaidrs ka neviena ekspedīcija nevar nodokumentēt pilnīgi visu, lai gan mēs jau esam kā Latviešu folkloras krātuve šajā vietā vismaz jau trešo reizi ekspedīcijā. Viena ir bijusi 1950. gados, otra - 1980. gados. Un tagad mēs esam šeit. Bet pirmo reizi mēs esam, koncentrējoties tikai uz Nautrēnu kultūrtelpu, un mūsu ir daudz, mēs esam gandrīz 20 pētnieki no piecām dažādām institūcijām, iestādēm un arī NVO. Arī fokuss ir mainījies, jo mēs neinteresējamies tikai par folkloras tekstiem, kas bija kādreiz ekspedīciju mērķis. Mūs interesē konteksts un ļoti dažādi konteksti šobrīd.” Latvijas Kultūras akadēmijas profesore Rūta Muktupāvela stāsta, ka viņu darba fokuss šoreiz ir kulturvēsturiskā mantojuma saglabāšana tā militāra apdraudējuma gadījumā. Rūta Muktupāvela: „Tieši Latvijas Kultūras akadēmijas interese ir drošības konteksts, kā vietējā kopiena, šajā gadījumā Nautrēnu kultūrtelpas pārstāvji, redz, kas ir tā viņu kultūrtelpa, kādas vērtības, gan materiālas, gan nemateriālas šeit ir, kādā veidā tās viņi glābtu, vai tas vispār ir nepieciešams, kāda ir iedzīvotāju loma, nevalstiskā sektora loma, līderpersonību loma. Visus šos jautājumus mēs risinām savu uzdevumu ietvaros, un tas ir tas jaunais - gan jauna situācija, gan jauna komponente, kad tiešām, mainoties situācijai, mainās pētniecība, mainās uzdevumi, un mēs esam pietiekami labi, lai spētu uz to reaģēt. Jebkurā gadījumā kultūras mantojums, tajā skaitā arī folklora un tradīcijas, un viss pārējais, kas ir tik ļoti svarīgs, ka tas nav sastindzis un tikai uz pagātni vērsts fenomens, ka tas dzīvo līdzās katrai situācijai, tajā skaitā arī ģeopolitiskajai situācijai, jo īpaši paturot prātā unikālo Nautrēnu kultūrtelpas situāciju, ka tā ir pierobeža. Un tieši mēģinām izrunāt, kā valsts var palīdzēt, kā pašvaldība var palīdzēt, kā katrs no mums varam palīdzēt saglabāt šo kultūras mantojumu, un sadalīt atbildību, un būt līdzatbildīgiem. Saprast valsts līmenī, cik nozīmīga ir katra valsts iedzīvotāja iesaiste visos šajos procesos, tieši nodrošinot ilgtspējību, noturību tieši pierobežā.” LFK vadītāja Rita Zara stāsta, ka sarunas ar cilvēkiem aizņem krietni vairāk laika, nekā sākumā varētu šķist. Klausīšanās un prasme uzturēt sarunu, ir viena no būtiskākajām pētnieciskā darba sadaļām, jo tieši tā izdodas iegūt vērtīgākos stāstus un liecības. Rita Zara: „Ievadā saku, aprunāsimies tikai 40 min., bet patiesībā aiziet divas stundas. Daudzi ir brīnišķīgi runātāji, visiem paldies, cilvēkiem ir fantastiskas zināšanas.” Kā piebilst profesore Rūta Muktupāvela, tad tieši plašais jomu un fokusu spektrs šoreiz veido ekspedīcijas unikalitāti.

81-erių vilnietė pardavė butą ir nusikaltėliui atidavė 114 tūkst. eurų. Tuo metu valstybės institucijos, NVO, verslininkai suka galvas, kaip dar padėti žmonėms nepakliūti į sukčių pinkles. Štai verslai ant kvitų spausdina patarimus bei numerį, kuriuo reikėtų skambinti įtarus, kad susiduria su nusikaltėliu. Ką mes visi dar galėtume padaryti, kad apsaugotume žmones nuo sukčių?Išsamiau – laidai „Už Vilniaus“ šią savaitę kalbėjo 34 parduotuves valdančio Ukmergės rajono vartotojų kooperatyvo vadovė Angelė Andrikonienė, Vietos bendruomenių organizacijų sąjungos pirmininkė Eglė Juozapavičienė, Vilniaus apskrities vyriausiojo policijos komisariato Kriminalinės policijos nusikaltimų nuosavybei tyrimo valdybos 2-ojo skyriaus viršininkas Olegas Bigbajevas.

In this June 2026 Mailbag, Jason and Jeff dive into OZEM, the world's first actively managed GLP-1 weight-loss drug ETF, debating whether its steep fees are worth outsourcing your portfolio research. They also explore how generative AI is shifting white-collar labor, detail exactly how they would allocate a surprise $250,000 windfall, and answer a critical valuation question on why pre-revenue player QuantumScape still commands a multi-billion dollar market cap.  03:36 Baseball Trash Talk 04:21 Mailbag GLP-1 ETF OZEM 08:04 Active ETF Pros and Cons 15:39 AI Disruption Question 16:37 SaaS and AI Native Future 20:58 AI in Construction and Trades 22:33 AI Productivity vs Disruption 24:07 AI Makes Us Dumber 27:19 Solid Power Overview 29:20 Battery Tech Commoditization 33:43 Windfall Money Plan 39:22 Spending vs Investing Choices 42:07 QuantumScape Market Cap Companies mentioned: ABNB, BMW, DAVA, F, GOOG, GOOGL, HIMS, KNSL, LEN, LLY, MELI, META, NOW, NVDA, NVO, PFE, PYPL, QS, RKLB, SLDP, TTD  Find where to listen & subscribe,  portfolio contests, and contact information at https://investingunscripted.com ***************************************** To get 15% off any paid plan at fiscal.ai, visit https://fiscal.ai/unscripted Listen to the Chit Chat Stocks Podcast for discussions on stocks, financial markets, super investors, and more. Follow the show on Spotify, Apple Podcasts, or YouTube ***************************************** Join our Patreon Subscribe to our portfolio on Savvy Trader. Use code Unscripted2026 for 30% off a one-year subscription! Learn more about your ad choices. Visit megaphone.fm/adchoices

It hasn't been in many headlines (thanks, AI), but pharmaceutical companies are on a merger & acquisition spree that could break records. With more than $126 billion in deals so far this year, companies are looking for novel drug canddiates and clinical stage companies to bolster their own development pipeline. We'll take a dive into what's driving this M&A frenzy and what companies look interesting in the pharmaceutical space today.Tyler Crowe, Matt Frankel, and Lou Whiteman discuss:- Big Pharma using big wallets for M&A- Who's at risk of running off a patent cliff- Regulatory changes adding fuel to the fire- Companies doing great for patients (and investors)- Mailbag: Is Pfizer ok? Companies discussed: LLY, MRK, UTHR, ASND, PFE, ABBV, GSK, NVO, RHHBYHost: Tyler CroweGuests: Matt Frankel, Lou WhitemanEngineer: Bart Shannon Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

SUMMARY DEL SHOW Futuros suben este jueves recuperándose de la caída de ayer, después de que la Fed mantuvo tasas sin cambios pero sorprendió con un tono más hawkish en su primera decisión bajo Kevin Warsh. $INTC sube 9% en premarket tras confirmarse que $AAPL se asocia con la compañía para fabricar chips de forma doméstica, impulsando a todo el sector de semiconductores. $QBTS avanza con un nuevo simulador de computación cuántica, mientras Wegovy oral gana terreno en las prescripciones de $NVO y $CI recorta cobertura de GLP-1 para sus empleados.

SUMMARY DEL SHOW Futuros con ligera presión antes del PCE, con el crudo repuntando por nuevos incidentes en Ormuz y la narrativa volviendo a energía, tasas y Fed. $SNOW se dispara tras cerrar un acuerdo a cinco años con AWS para asegurar acceso a Graviton, una señal de “capacidad garantizada” en plena explosión de demanda por AI. Drones se recalientan por el plan “Drone Dominance” y $CVS decide volver a cubrir Zepbound de $LLY en parte de sus listas, subiendo la competencia frente a $NVO.

SUMMARY DEL SHOW Futuros casi planos a levemente verdes tras el rally de ayer. El mercado está en modo wait and see, con Irán y petróleo como ruido principal, pero con esperanza de conversaciones que bajen tensión. Hoy mandan dos catalíticos. Sale PPI con presión esperada por energía. Arranca earnings con bancos como $JPM y $WFC, y el mercado busca señales de crédito, trading y tasas altas. $AMZN podría comprar $GSAT para reforzar Project Kuiper. $ORCL amplía alianza con $BE para energía on-site en data centers. $NVO anuncia alianza con OpenAI para IA en I+D y operaciones.

SUMMARY DEL SHOW Futuros levemente en rojo mientras el mercado enfría el relief rally. La tregua con Irán se ve frágil, el petróleo rebota y el tape vuelve a depender de titulares. $STAA se dispara tras adelantar ventas de 1T por encima de $90M y señalar mejora fuerte en EBITDA ajustado, con China como motor principal. $DIS planea recortar cerca de 1,000 puestos para simplificar marketing. En India, genéricos de semaglutida están cambiando el balance de $NVO y $LLY y podrían anticipar el impacto de los patent cliffs.

SUMMARY DEL SHOW Futuros levemente en verde tras extenderse hasta abril la pausa de ataques a infraestructura energética de Irán. Baja un poco la tensión en petróleo, pero el riesgo de titulares sigue alto. $NFLX sube precios en EE. UU. para financiar más contenido y empujar ARPU. $NVO recibe aprobación de la FDA para Awiqli, insulina basal semanal. Flujos vuelven a acciones de EE. UU. con la mejor semana en cuatro meses. Entraron $37.24 Billones netos, con preferencia por large caps y Treasuries de corto a intermedio plazo.

Kultūras rondo izvaicājam Nacionālās skatuves mākslas skolas jauno katedras vadītāju Maiju Pavlovu. Maiju Pavlovu jau vairāk nekā 15 gadus zinām kā Ģertrūdes ielas teātra producenti, kura aktīvi darbojas arī kultūras jomas nevalstisko organizāciju interešu aizstāvībā valsts līmenī caur Laikmetīgās kultūras NVO asociāciju. Bet šogad viņa ir pieņēmusi jaunu izaicinājumu un kļuvusi par Latvijas Kultūras akadēmijas Nacionālās Skatuves mākslas skolas vadītāju. Š posteni viņa pārņem no Līgas Ulbertes, kura Skatuves mākslas katedru vadīja iepriekšējā termiņā.

Sieviešu līdztiesības jautājumi, vardarbības problēmas vienmēr izraisa asas diskusijas. Var minēt, kādēļ, bet skaidrs, ka būtiskas pārmaiņas attiecībā uz sieviešu tiesībām ir nesena pagātne, ja lūkojamies sabiedrības vēsturē kopumā. Mūsdienās sievietes ir augstākajos valsts amatos, sievietes drīkst darīt visu to pašu, ko vīrieši, šķēršļu nav. Kādēļ arvien runājam par līdztiesības problēmām? Par šiem jautājumiem runājam Krustpunktā ar biedrības "Latvijas Sieviešu nevalstisko organizāciju (NVO) sadarbības tīkls" valdes priekšsēdētāju Inetu Ielīti.  

SUMMARY DEL SHOW Futuros en rojo pero recuperando parte del golpe nocturno: el crudo baja desde niveles cerca de $120, aunque el mercado sigue en modo risk-off por el conflicto y Ormuz. Petróleo >$100 mantiene miedo a inflación y golpe al consumo; el G7 evalúa liberar reservas, y el mercado ya mira CPI miércoles y PCE viernes. $HIMS salta >50% por posible acuerdo de distribución de GLP-1 con $NVO; $OKLO y $LEU exploran JV para fortalecer cadena de suministro de HALEU.

SUMMARY DEL SHOW Futuros caen fuerte por escalada en Medio Oriente: crudo más caro vuelve a presionar crecimiento e inflación y complica el timing de recortes de la Fed. Golpe directo a semis: KOSPI $KOSPI se desploma ~7%, Samsung $SSNLF y SK Hynix $HXSCF caen ~10%–11%; contagio en EE. UU. pega a $NVDA, $AMD, $AVGO, $MU, $ASML y $LRCX. Morgan Stanley sube $NVO a Equal weight, pero recorta PT y ve 2026 como transición; destaca tracción de Wegovy Pill y mantiene a $LLY como rival clave.

SUMMARY DEL SHOW Futuros en rojo por más incertidumbre comercial: Trump subiría el arancel global de 10% a 15% tras el fallo de la Corte Suprema, presionando el apetito por riesgo. $NVDA prepara su regreso a PCs de consumo con chips para laptops centrados en IA junto a $DELL y $LNVGY, reforzando el “AI PC cycle”. Cripto bajo presión por salidas de ETFs de bitcoin y $NVO se desploma tras datos de CagriSema, mientras $LLY se fortalece.

SUMMARY DEL SHOW Wall Street arranca la semana en negativo antes de una agenda macro pesada: empleo el miércoles y CPI el viernes; suben rendimientos y eso presiona a tech. $HIMS cae fuerte tras dejar el semaglutide “copycat”, mientras $NVO sube; la FDA endurece postura contra compuestos cuando ya no hay escasez. TotalEnergies $TTE acuerda 1 GW solar para data centers de $GOOG / $GOOGL en Texas y $BTC vuelve a caer por debajo de $70K.

After Eli Lilly (LLY) posted earnings that outshined Novo Nordisk's (NVO) decelerating growth, Scott Zari feels comfortable calling Eli Lilly the dominant winner in the weight loss drug race. While he notes Novo Nordisk's pill as "important" to consumers, it's Eli Lilly's injectable he sees continuing to lead GLP-1 momentum. Tom White offers an example options trade for Eli Lilly. ======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Big pharma and biotech take the earnings stage this week with reports from Eli Lilly (NYSE: LLNY) and Novo Nordisk (NYSE: NVO) leading the lineup. Will they help the industry once again outperform AI champ NVIDIA (NASDAQ: NVDA), as the industry did in 2025? Karl Thiel, Tom King, and Tim Beyers discuss: - Slow rolling chaos at FDA and its effects on drug approvals. - How to think about risk when investing in biotech. - Earnings predictions for Lilly and Novo as well as a review of results from DNA researcher Twist Bioscience (NASDAQ: TWST). Don't wait! Be sure to get to your local bookstore and pick up a copy of David's Gardner's new book — Rule Breaker Investing: How to Pick the Best Stocks of the Future and Build Lasting Wealth. It's on shelves now; get it before it's gone! Companies discussed: RGNX, LLY, NVO, TWST Host: Tim Beyers Guests: Karl Thiel, Tom King Producer: Anand Chokkavelu Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

En este cierre de año, Wall Street busca impulso mientras los mercados se preparan para una semana corta por las festividades. Aquí están los temas clave del día:

I've been refining my process for longer-term holds, and the market just handed me 5 painful but valuable lessons.In this episode:Management Integrity: If they miss guidance, get out.Buy the Leader: Don't nurse the loser (NVO) when the winner (LLY) is running.Positioning: Be okay with half-size until the chart proves you right.Crowded Trades: Beware of "Value" stocks that are actually just stuck longs.Execution: Never add to a loser until fundamentals and technicals improve.Listen in for the full breakdown.

There are so many good opportunities in the market. It's about finding them and using the fundamental and technical metrics to find entries and understanding when you want to sell (either at a gain or loss). BLACK FRIDAY SALES END SOON: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TRENDSPIDER - Up to 68% off and 52 trainings for the next year. HUGE SALE saving you over $1,000. ⁠⁠⁠⁠⁠⁠SEEKING ALPHA BUNDLE - Save over $200⁠⁠⁠⁠⁠⁠Seeking Alpha Premium - FREE 7 day trial ⁠⁠⁠⁠⁠⁠Alpha Picks - Save $100 ⁠⁠⁠⁠⁠⁠Seeking Alpha Pro - for the Pros ⁠⁠⁠EPISODE SUMMARY $LLY  joins the $1T club—GLP-1 growth, strong management, and blockbuster drug pipeline!$NVO  drops on Ozempic's Alzheimer's miss; $AAPL  just 2% from all-time highs.$AMD  upgraded to “Strong Buy” after memory supply squeeze; $TSLA  is now a chip & AI leader with FSD impressing on long trips.$GOOG  Gemini supercharges AI with custom chips, and $CRM  CEO raves about it—AI bubble or generational opportunity?Goldmans  points to high-profile shorts and surprises for this week, plus $MU , $COMM , $CLS  hit the Expert Picks list as top AI/value setups.Plus: Global rotation opportunities, ETF sentiment, and crypto's new cross-currents!Don't miss the detailed analysis, actionable takeaways, and the week's hottest charts—read and subscribe atdailystockpick.substack.com#StockMarket #AIStocks #TechLeaders #BlackFridayDeals #GrowthInvesting #DailyStockPickDon't forget to like, subscribe, and share.Social Links and more - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/dailystockpick⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

En el episodio de hoy, el foco se divide entre avances tecnológicos, tropiezos en el sector farmacéutico y el rebote del mercado mientras se acerca una semana corta pero cargada de datos económicos clave:

Timestamps:6:03 – Breakdown of FICO15:15 – Futures Trading Tip of the Week18:37 – Trump's $2K Tariff Plan34:46 – Burry's Shorts on NVDA & Palantir46:00 – What to Do After Becoming a Millionaire59:00 – Is Google the Sleeper AI Giant?1:04:10 – Holiday Market Play: Crypto or Stocks?1:08:20 – Trump x NVO x LLY Partnership Breakdown1:15:46 – Pre-Recession Indicators to Watch1:24:53 – CMG vs. CAVA Investment Outlook1:28:20 – End of Government Shutdown1:32:00 – Key Market Indicators for 20271:33:22 – Weekly Earnings RecapIn this week's Market Mondays, we break down everything from Trump's $2,000 plan to the future of AI and the latest market indicators signaling what's ahead for investors.We start with a deep dive into FICO scores and how they impact your financial future, then move into futures trading tips and Trump's bold plan to give every American $2,000 from tariff profits.We also discuss Michael Burry's short positions against Nvidia and Palantir, whether Google is the sleeper giant in AI, and what to do after you become a millionaire.Plus — we analyze Trump's new partnership with Novo Nordisk and Eli Lilly, what it means for biotech investors, and which markets — crypto or stocks — to focus on during the holiday season.As the government shutdown ends, we reveal key pre-recession indicators to watch, whether Chipotle (CMG) or CAVA are smart plays right now, and what signals could define the path to 2027.#MarketMondays #EarnYourLeisure #Investing #StockMarket #Crypto #FuturesTrading #TrumpEconomy #AIStocks #NVDA #Google #Palantir #NVO #LLY #FinancialEducation #WealthBuilding #RecessionPrep #EYLOur Sponsors:* Check out PNC Bank: https://www.pnc.com* Check out Square: https://square.com/go/eylSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

In this week's episode of Dividend Talk we kick off with Kimberly-Clark's surprise move to buy Kenvue, asking if it's a smart acquisition or a future balance-sheet headache. Then we review Q3 earnings from Novo Nordisk, Wolters Kluwer, and Ahold Delhaize, three European dividend powerhouses facing very different challenges.Novo Nordisk's obesity drugs, valuation reset, and dividend safety dominate the discussion, while Wolters Kluwer's high-PE sell-off and the impact of AI on research businesses spark debate on fair value and buybacks. We also look at Snap-on's double-digit dividend hike and Simon Property Group's steady income growth for REIT investors.Later, we revisit our “Monthly Dividend Portfolio” challenge from 2022, checking how picks like Altria, AbbVie, Johnson & Johnson, Realty Income, Shell, and Texas Instruments performed with lessons on dividend growth, yield, and diversification.In the listener Q&A, we cover:Dividend tax strategies and EU exit taxes How to handle rising wealth taxes as a dividend investor Fair-value analysis vs Morningstar valuations Our take on Volkswagen, General Mills, GreenCoat UK, ExxonMobil vs Chevron, and the global renewable-energy transition Thoughts on Unilever's upcoming Magnum spinoff SEE YOU ON THE INSIDE!!Tickers discussed: KMB, KVUE, NVO, LLY, PFE, WKL.AS, AD.AS, SNAP-ON, SPG, MO, ABBV, JNJ, O, TXN, SHEL, GIS, XOM, CVX, UKW.LJoin us:[Facebook] – Https://www.facebook.com/groups/dividendtalk⁠[Twitter] – @DividendTalk_ , @European_DG[Discord] – ⁠https://discord.gg/nJyt9KWAB5⁠[Premium Services] – ⁠https://dividendtalk.eu/download-your-free-samples/⁠[Malmo Meetup] – ⁠https://t.co/STgV1nMWKj

In this week's episode of Dividend Talk, we're back with Q3 Earnings Roundup.We kick things off with Novo Nordisk shaking up half its board of directors, before covering two big dividend announcements from McDonald's and Amphenol. Then it's over to earnings, where we break down results from Germany's Mensch und Maschine, Danaher, Evolution Gaming, and Texas Instruments.We also review a listener portfolio from “Bella Dividends,” packed with high-yield European names, and share our thoughts on diversification, growth balance, and dividend safety.In the Q&A, we talk estate tax and brokers, the future of quarterly reports, DCF vs. dividend discount models, and stock-specific questions on Intel, TotalEnergies, Watsco, and GreenCoat UK.SEE YOU ON THE INSIDE!!Tickers discussed: NVO, MCD, APH, MUM.DE, DHR, EVO.ST, TXN, SHEL, IBM, TTE, INTL, WSO, RELAS, IBDR.MC, VWS.COJoin us:[Facebook] – Https://www.facebook.com/groups/dividendtalk⁠[Twitter] – @DividendTalk_ , @European_DG[Discord] – ⁠https://discord.gg/nJyt9KWAB5⁠[Premium Services] – ⁠https://dividendtalk.eu/download-your-free-samples/⁠[Malmo Meetup] – https://t.co/STgV1nMWKj

Summary del Show: • Wall Street retrocede con fuerza por temores sobre bancos regionales y riesgo crediticio. • $MU se desploma tras decidir frenar envíos de chips para servidores en China. • $META asegura $30B en financiamiento privado para el mayor centro de datos de IA del mundo. • Trump anuncia recorte drástico en precios de Ozempic, golpeando a $NVO y $LLY.

65 Profecias del A.T. Que se cumplen en el Nvo. Testamento 14/10/25

Some drug stocks are cheap but is it another fake out? (0:30) - Can You Find Strong Value Investments In Drug Stocks Right Now? (3:40) - Breaking Down The Recent Industry Performance (9:00) - Tracey's Top Stock Picks (30:00) - Episode Roundup:  PFE, MRK, ABBV, LLY, NVO

Morgan Stanley now holds the most pessimistic view of Novo Nordisk's (NVO) stock. It downgraded the company to underweight from equal weight and set a Street-low price target of $47. Marley Kayden talks about how the company's Alzheimer trials for one of its treatments played a key role in the downgrade. Prosper Trading Academy's Charles Moon goes against the tide and explains why he sees short-term potential through an example options trade.======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

In this episode, we dive into the realities of dealing with portfolio drawdowns as dividend growth investors. From personal examples to strategies for averaging down, price anchoring, and knowing when to hold or sell, we share how we manage the emotions that come with falling share prices.We also cover the latest news and dividend hikes, including:Novo Nordisk – promising results from its new oral weight-loss drugLondon Stock Exchange Group – stepping into blockchain with MicrosoftIntel & Nvidia – surprising partnerships in the chip industryTexas Instruments, Microsoft, W.P. Carey, and Philip Morris – dividend hike updatesPlus, we review Bradley's dividend portfolio and answer listener questions on hedging against USD, quick dividend stock screeners, reinvestment strategies, tax-efficient accounts, and more.

S&P Futures are higher after the Fed's “risk management” rate cut. Powell signaled caution, but the Dot Plot hints at two more cuts in 2025. In corporate headlines: DIS halts its late-night show under FCC pressure, META debuts next-gen smart glasses, and NVO rises on Ozempic data showing lower heart-attack risk. Looking ahead—Trump and Xi's Friday call could finalize a TikTok deal, plus cover trade on soybeans and Boeing jets. Key data: jobless claims this morning. Earnings: CBRL underwhelms despite a beat, FDS misses, with DRI, LEN, and FDX still to report.

The Silly History Boys most Dear Uncle is off on tour with the Story Forge Show! And YOU are invited…on an hilariously unique family-friendly theatrical adventure!  Join the ludicrously learned (and undeniably loopy) duo, Professor Doctor Lee Hithersay and Doctor Professor Robert Rhys Bond, as they embark on a quest to forge three brand-new myths live on stage! Will your adventure unfold on the sun-drenched shores of Ancient Egypt, amidst the icy fjords of Viking legend, or in the inky depths of Neptune's ocean? The choice is yours! Shape the narrative, suggest the world, and even take centre stage as the hero of your very own myth (participation entirely optional, shy souls still welcome!). Forge your own unforgettable story and become a legend – you'd be mad to myth it! Nice Things People have said about Story Forge...     TICKET LINKS and Venues all Below      Suitable for ages 7+ Running time 1 hour and no interval     Derby Theatre September 20th, 11am and 2pm https://derbytheatre.co.uk/event/story-forge/     Maesteg Town Hall November 6th at 1.30 https://awenboxoffice.com/whats-on/the-story-forge-make-your-own-myth/   Hoole Community Centre in Chester September 21st at 1.30pm https://www.ticketsource.co.uk/whats-on/chester/hoole-community-centre/rubbish-shakespeare-company-silly-history-boys-the-story-forge-make-your-own-myth/e-lellam   Chelmsford theatre, Saturday the 27th of September  11.30 and 14.30 https://www.chelmsfordtheatre.co.uk/event/the-story-forge-make-your-own-myth   Farnham Maltings, the Great Hall, Sunday the 28th of September. 11am and 2.30 https://farnhammaltings.com/events/the-story-forge   Friday the 3rd of October, 6pm https://www.ticketsource.co.uk/whats-on/chester/tarvin-community-centre/the-story-forge-make-your-own-myth-the-rubbish-shakespeare-company-silly-history-boys/e-xokpvr    Gosforth Civic Theatre, 4th of October, Newcastle 11am and 2pm https://www.gosforthcivictheatre.co.uk/whats-on/the-story-forge-make-your-own-myth   Queens Hall Hexham, 5th of October, at 2pm https://www.queenshall.co.uk/whats-on/the-story-forge-make-your-own-myth   The Stables Milton Keynes, 11th of October at 2pm  https://stables.org/event/rubbish-shakespeare-company-the-silly-history-boys-the-story-forge   Story Forge Warwick Arts Centre, October 12th. 11.30 and 2.30 https://www.warwickartscentre.co.uk/whats-on/nvO-the-story-forge-make-your-own-myth/   Story Forge Armly/Leeds, St Bartholomew church, for Red Ladder Theatre Company  https://www.redladder.co.uk/whatson/story-forge/   Dorman Museum November 9th. 11.30 and 2.30 https://online1.venpos.net/ConsumerSite/VisitDateTime?LID=936&PID=440cf6d7-e6ee-48c9-aee5-b0e31a1d3d1a&LNG=en&VD=2025-11-09T00%3A00%3A00     The Story Forge was banged together with the molten talents of these nice people…   Performed by Lee Hithersay, Robert Rhys Bond and Oliver Wilson, Ryan Byrne and Daniel Bradley  Props and costume design by Alice Rowbottom Set design by Alex MacDonald Lighting Design by Beccy Hillam Written by Robert Rhys Bond and Lee Hithersay Directed by Mark Smith    

There are new ways to tackle weight loss, but the stocks leading the way are lagging. Today on Motley Fool Money, Rick Munarriz, with analysts Karl Thiel and Jason Hall dig into the problems with weight loss stocks. There's also a look at some investments that can survive next month's potential volatility as well as a long-term view at disruptors of the future that you probably didn't see coming.  They unpack: Three companies that can ride high through what could be a volatile September. A reality check for GLP-1 and other weight loss stocks. Finding the next great disruptor that could be hiding in plain sight. Companies discussed: VKTX, NVO, LLY, UNH, TREX, DIS, TBBB, LEN  Host: Rick Munarriz, Karl Thiel, Jason Hall  Producer: Anand Chokkavelu Engineer: Bart Shannon Learn more about your ad choices. Visit megaphone.fm/adchoices

This week on Dividend Talk, Derek is joined by Jeremy from Dividend Stockpile to explore some of the biggest Megatrends shaping our investing future. We cover the opportunities and risks in infrastructure, clean energy, technology, and healthcare, and how dividend investors can position themselves for the next decade and beyond.You'll hear about recent dividend news from Interface (TILE) and Agree Realty (ADC), how US and European infrastructure approaches differ, why utilities like Iberdrola (IBE.MC) and Enel (ENEL.MI) stand out, and how tech giants Meta (META), Alphabet (GOOG), and Microsoft (MSFT) fit into the AI megatrend. We also look into healthcare innovation, options income strategies, and favourite finance content creators.Tickers Mentioned: TILE, ADC, O, BAM, BIP, NEE, DUK, ED, IBE.MC, ENEL.MI, ABB, DG.PA, META, GOOG, MSFT, GE, CWEN, ASML.AS, SAP, MDT, MRK, ABBV, NVO, LLY, ROG.SW, SNY, SYK, ABT, BDX, RMD, STRCChapters:00:00 – Introduction & Guest Welcome02:52 – Company News: Interface & Dividend Increases05:41 – Agree Realty & REIT Quality08:43 – Understanding Megatrends11:51 – Infrastructure as a Megatrend29:06 – Clean Energy Transition39:31 – The Rise of Technology & AI46:51 – Healthcare Opportunities01:04:06 – Options Income Strategies & High Yield Ideas01:20:06 – Favorite Finance Content Creators & Closing RemarksGet a free sample of our premium dividend newsletter! Stay ahead of the market with in-depth stock analysis here: https://dividendtalk.eu/download-your-free-samples/ Stay Updated:Twitter - @DividendTalk_Twitter - @European_DGIJoin our Facebook Community - Dividend Talk Facebook GroupJoin our Discord group - https://discord.gg/nJyt9KWAB5

In this week's episode of Dividend Talk, we kick off with our Q2 performance review , looking at how our dividend portfolios fared, what we bought, sold, and learned over the past quarter.  We also dive into three big names making headlines: Wolters Kluwer's sharp share price drop and the fear of AI disruption, Novo Nordisk's earnings and competition with Eli Lilly, and UnitedHealth's reduced outlook.  Along the way, we cover dividend hikes and cuts from around the globe, have some laughs over corporate slogans, and answer a packed list of listener questions ranging from sector risks to portfolio construction. SEE YOU ON THE INSIDE!! Tickers discussed: WKL.AS, NVO, LLY, UNH, HEIA.AS, NN.AS, AD.AS, ITW, CLX, AWR, WHR, LGEN.L, MRK, LVMH.PA, TGT, LYB, NKE,CVX, HPQ, MSFT, SHEL, BTI, BAM, BAES.L, HORNB.BR, UPS, PEP, CCOI, ORA.PA,ASR.AS, ASML.AS, UL, GLB.IR, KRZ.F, KESKOB.HE, KNEBV.HE, SAMPO.HE, AGE.BR, XIOR.BR,ASC.BR, SHL.DE, DEF.F, NVO-B.CO, VICI, RY, DOL.TO, FTS.TO, UKW.L, VOLVB.ST,INVE-A.ST, INVE-B.ST, SEB-A.ST, SWED-A.ST, HAND-B.ST, SHELL.AS, VIE.PA, O,SECUB.ST, ABBV, BAYN.DE.  Join us :[Facebook]  - Https://www.facebook.com/groups/dividendtalk[Twitter] -   @DividendTalk_    ,  @European_DG[Discord] - https://discord.gg/nJyt9KWAB5[Premium Services] - https://dividendtalk.eu/how-it-works

My portfolio was way up yesterday - it's happened during 2 kinds of periods in the market. And we've got another day of HUGE earnings. Plus some other opportunities. Here are the links to all the sales: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SAVE ON TRENDSPIDER - GET THE ANNUAL SUBSCRIPTION TO GET MY 4 HOUR ALGORITHM ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Summary del Show: • Wall Street arranca al alza con la Fed en el centro del escenario, mientras se esperan señales de Powell y los resultados de $MSFT y $META tras el cierre. • $SBUX sube tras sorprender con ventas y un plan agresivo de renovación, destacando su crecimiento en China y nuevas inversiones en tiendas y servicio. • $NVO cae al recortar su guía 2025 por menor demanda de semaglutida en EE.UU., aunque analistas ven la caída como oportunidad de compra. • Google $GOOGL acepta firmar el Código de IA de la UE, a pesar de las tensiones sobre derechos y competitividad.

Between battered industries and overlooked opportunities, plenty of dividend-paying companies have slipped to the bottom of the earnings jar. Today, Emily Flippen, Matt Argersinger, and Ant Schiavone dig into: The shrinking ranks of “Dividend Knight” contenders Healthcare stocks with hard times but high yields What investors should prioritize in dividend-paying stocks Companies discussed: NVO, UNH, WHR, PLD, CNQ, SCHDHost: Emily Flippen, Anthony Schiavone, Matthew ArgersingerProducer: Anand ChokkaveluEngineer: Adam Landfair, Natasha HallDisclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. Learn more about your ad choices. Visit ⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Stocks closed down as tariff talks between the U.S. and China continued for a second day in Sweden. Most earnings didn't offer hope for positive trading action, seen in Novo Nordisk's (NVO) 22% decline after curbing sales expectations for Wegovy and Ozempic. Spotify (SPOT) also saw a staggering sell-off after posting a surprise miss. However, SoFi Technologies (SOFI) offered a bright spot with its rally. Marley Kayden talks about the biggest earnings movers of the session.======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Summary del Show: • Mercado mixto antes de datos clave: Los futuros abrieron casi sin cambios tras rumores sobre Powell y un IPP suave. Hoy destacan ventas minoristas, solicitudes de desempleo y resultados de $NFLX. • Avanza legislación cripto en el Congreso: La Cámara impulsa tres leyes clave, incluyendo el GENIUS Act y el CLARITY Act; se espera voto final esta semana. • Europa lanza supercomputadora cuántica con $MSFT: Dinamarca y la fundación de $NVO invertirán 93 Millones de dólares en el proyecto QuNorth para competir globalmente. • WeRide lanza primer Robobus sin operador en Asia sudoriental: El servicio opera en Singapur y marca un hito en movilidad autónoma, mientras la acción sube +1.48%.

Amazon's latest data center will require the same amount of electricity as one million homes. (00:21) Jason Moser and Matt Argersinger join Ricky Mulvey to discuss: - The data center spending boom. - Hims & Hers messy breakup with Novo Nordisk. - Overrated and underrated business stories from the year so far. (19:11) Progyny CEO, Peter Anevski, joins Tim Beyers and Holly Anderson to discuss the growth path ahead for the health benefits company. (31:28) Jason and Matt discuss Disney's box office struggle with “Elio” and offer up two radar stocks: Uber and Otis Worldwide. Companies discussed: AMZN, HIMS, NVO, TSLA, PGNY, DIS, UBER, OTIS Host: Ricky Mulvey Guests: Jason Moser, Matt Argersinger, Tim Beyers, Holly Anderson, Peter Anevski Engineer: Dan Boyd Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, "TMF") do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. Learn more about your ad choices. Visit megaphone.fm/adchoices

Novo Nordisk parts ways with Hims & Hers, a financials-related stock to get on your radar and more! Jason Moser and Matt Frankel discuss: - Why Novo Nordisk is parting ways with Hims & Hers. - Waymo and Uber's big Atlanta debut. - What the potential tax deduction on autos could mean for consumers and companies. - Matt has a financials-related stock he thinks is worth a closer look. Tickers mentioned: NVO, HIMS, TSLA, UBER, GOOG, GM, ALLY, RKT Host: Jason Moser Guest: Matt Frankel Engineer: Dan Boyd Learn more about your ad choices. Visit megaphone.fm/adchoices

En este episodio cubrimos los eventos más relevantes antes de la apertura del mercado: • Wall Street sube pese a tensiones en Medio Oriente: Futuros en verde: $SPX +0.8%, $US100 +1.2%, $INDU +0.8%. Los rendimientos del Treasury caen levemente. Israel acusó una violación del alto al fuego y amenaza con represalias, mientras Irán niega nuevos ataques. El permiso para civiles de abandonar refugios en Israel trajo algo de alivio. Hoy se publican datos de precios de vivienda, confianza del consumidor y testifica Powell en el Congreso. • IBM despliega sistema cuántico avanzado en Japón: $IBM y el laboratorio RIKEN inauguraron el primer IBM Quantum System Two fuera de EE.UU., ubicado en Kobe. El sistema utiliza el procesador Quantum Heron de 156 cúbits, el más avanzado de la compañía. Apoyado por NEDO, el proyecto busca combinar supercomputación y computación cuántica en la era post-5G. • Novo Nordisk lanza Wegovy en India: $NVO presentó oficialmente su medicamento para pérdida de peso en el mercado indio. Wegovy se venderá en cinco dosis, con un costo mensual entre $50 y $312. La competencia con $LLY se intensifica tras el lanzamiento de Mounjaro en el país. $NVO +1.95% premarket. • Mastercard y Fiserv integran stablecoin FIUSD: $MA fortalece su alianza con $FI al integrar la stablecoin FIUSD en su red global. La plataforma digital de Fiserv se lanzará en 2025 y busca facilitar soluciones para bancos y adquirentes. $FI +6% premarket tras el anuncio. Una jornada con atención en geopolítica, avances tecnológicos y nuevos frentes en salud y pagos digitales. ¡No te lo pierdas!

Hims & Hers (HIMS) shares are reeling after Novo Nordisk (NVO) severs its weight-loss drug relationship with the telehealth company. NVO claims HIMS was marketing knock-off weight loss drugs using "deceptive promotion" tactics. George Tsilis weighs in on why HIMS is down 30% on the news, and how it impacts the company's personalization care business segment. He points to possible red flags with ingredients coming from China and a lack of quality control over the use of weight-loss medication.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Fed Chair Powell and team want to see more before making changes to interest rates, and automakers are an early sign price increases might be coming in response to tariffs. (00:21) Tim Beyers and Bill Mann discuss: - The Fed's continued wait and see approach to tariff policy, inflation, and interest rate cuts. - Ford's warning of tariff impacts, and why MercadoLibre is worth a look amid the macro uncertainty. - How Uber and DoorDash are both flourishing as they cash in on the delivery market and consumer laziness. (19:11) Fool contributor Jason Hall talks through his time at Berkshire Hathaway's annual meeting in Omaha, Warren Buffett's plans to step down as CEO, and what to expect next from Greg Abel. (31:12) Bill and Tim break down two stocks on their radar: Apple and Ibotta. Stocks discussed: F, MELI, DASH, UBER, NVO, BRK.A, BRK.B, AAPL, BAC, IBT Host: Dylan Lewis Guests: Bill Mann, Tim Beyers, Jason Hall Engineers: Dan Boyd Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, "TMF") do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. Learn more about your ad choices. Visit megaphone.fm/adchoices

The big game didn't live up to the big billing, but there was plenty to take in during commercial breaks and halftime. (00:14) David Meier and Dylan Lewis discuss: - HIMS taking a big swing at the weight-loss industry, trying to seize a tight window for acquiring customers that want GLP-1 drugs and shift public opinion on them. - Dunkin' and Starbucks taking very different approaches for morning coffee drinkers. - McDonald's lackluster Super Bowl ad and earnings results. WSJ article on HIMS: https://www.wsj.com/health/pharma/hims-super-bowl-ad-spotlights-weight-loss-drug-copycats-as-clock-ticks-on-their-business-3a225c5c (21:35) Robert Brokamp and Alison Southwick continue their conversation on 401ks and how you can get yours in better shape. Companies discussed: HIMS, LLY, NVO, SBUX, SKX, MCD Host: Dylan Lewis Guests: David Meier, Robert Brokamp, Alison Southwick Producer: Ricky Mulvey Engineers: Rick Engdahl Learn more about your ad choices. Visit megaphone.fm/adchoices